Cerenome

09/18/2026

The American Brain Tumor Association’s 2026 National Conference begins today; come visit our booth!

will be at to connect with patients, advocates, and fellow industry experts to discover more about the latest advances in research, treatment and care.

09/16/2026

announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide Diagnostics, strengthening relationships across the and communities, and accelerate adoption of the platform by physicians and health systems.

Read the full press release here: https://bit.ly/3Vh0B5D

09/14/2026

Impactful clinical data from UCSF highlighting the critical role of CSF liquid biopsy in patients with metastatic and .

Read the study snapshot here: bit.ly/4iLPVpF

09/10/2026

announces that it has entered into a financing agreement with 3i, LP (3i Fund) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, received initial funding at closing, with future tranches available upon achieving certain milestones.

The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide Diagnostics’ cerebrospinal fluid assay platform.

Full press release here: https://bit.ly/4A40drh

Nasdaq

09/09/2026

The team was proud to bring together expert leaders in to discuss the evolving management of the disease in our dedicated symposium at the 2026 SNO/ASCO CNS Metastases Conference last month.

Key opinion leaders Jessica Wilcox, MD, Michael Youssef, MD, and Rupesh Kotecha, MD, led the presentation and highlighted key research across both Cerenome’s ™ clinical development program and CNSide Diagnostics' cerebrospinal fluid diagnostic platform.

Check out the full recording here: https://bit.ly/4zYuIip

American Society of Clinical Oncology

09/03/2026

September is and ’s ReSPECT-PBC U.S. Phase 1 is actively recruiting pediatric patients.

If a patient in your care may be eligible, please connect with our team via the form on our website: https://bit.ly/4y8yLa9

09/01/2026

Thank you to Nasdaq for displaying this congratulatory message in Times Square to celebrate our rebrand to and stock ticker change to .

08/26/2026

As we look ahead to in September, we are reminded of the urgent need for new therapeutic options. Brain and spinal cord tumors are the second most common cancers in children and the leading cause of disease-related death among pediatric patients in the U.S.

We are pleased to share that the ReSPECT-PBC U.S. Phase 1 Clinical Trial is now actively recruiting patients!

If a patient in your care may be eligible, we encourage you to discuss this with their physician and connect with our team to learn more.

Learn more & check eligibility: https://bit.ly/4y8yLa9

08/24/2026

's CEO and President, Dr. Marc Hedrick, spoke with Fintech.TV about the key updates behind our recent rebrand from Plus Therapeutics and what it means for the future of the company.

Dr. Hedrick walks through ’s broader corporate vision, the transition from being a single asset company to a dedicated platform, how the strategic combination of therapeutics, advanced , and seeks to improve , and the expansion of our team’s capabilities from from diagnosis to treatment.

Check out their full interview: https://bit.ly/4gfbMUH

Nasdaq CNSide Diagnostics

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

08/21/2026

What an incredible week for at the 2026 SNO/ASCO CNS Metastases Conference!

From the well-attended booth and poster sessions from Dr. Andrew Brenner and Dr. Kelly Kreitzburg Ondrasek to a packed house for our “Redefining the Management of Leptomeningeal Metastases” symposium with Dr. Jessica Wilcox, Dr. Michael Youssef, and Dr. Rupesh Kotecha, the team was proud to make a strong impact on discussions at what was an incredibly active conference.

Take a look at some of the highlights from our busy week!

American Society of Clinical Oncology